Editor in Chief

Acta Scientific Paediatrics (ASPE)


  • Name
  • Specialization
  • Experience
  • Date of birth
  • E-mail
  • Mobile No
  • Address
  • : Prof. Antonio Ruggiero
  • : Pediatric Oncology
  • : 25 Years
  • : November 01, 1967
  • :antonio.ruggiero@unicatt.it
  • : +39-3356732269
  • : Catholic University of Rome,Largo A. Gemelli, 1, 20123 Milano MI, Italy.

Current Affiliation

Aggregate Professor in Pediatric Oncology, Catholic University of Rome,Largo A. Gemelli, 1, 20123 Milano MI, Italy.

Qualifications

  Medical Degree, 110/110 cum laude Universita’ Cattolica del Sacro Cuore, Roma.
  Board of Pediatrics, 50/50 cum laude Università Cattolica del Sacro Cuore, Roma.
  Board of Pediatric Haematology and Oncology, 50/50 cum laude Università Cattolica del Sacro Cuore, Roma.

Experience

  Catholic University of Rome, Department of Pediatrics, Resident in General Pediatrics.
  Catholic University of Rome, Department of Pediatrics, Resident in Pediatric Oncology.
  Catholic University of Rome, Department of Pediatrics, Division of Pediatric Oncology, Consultant in Pediatric Oncology.
  Catholic University of Rome, Department of Pediatrics, Division of Pediatric Oncology, Aggregate Professor in Pediatric Oncology.
  Royal Liverpool Children’s NHS Trust – Alder Hey Hospital, Oncology Unit, Locum Consultant Paediatric Oncologist.
  Catholic University of Rome, Department of Pediatrics, Division of Pediatric Oncology, Head of the Pediatric Hematology and Experimental Therapies Unit.
  National Academic Qualification as Associate Professor.

Academic Awards and Activities

  Cytotoxicity of new cisplatin’ analogues on neuroblastoma cell lines”.Italian Ministry of University.
  “Preclinical studies on antineoplastic efficacy of new platinum compounds in neuroblastoma”. Italian Ministry of University.
  “Case-control study on leukemias, neoplasms and growth delay in children exposed to magnetic fields”. National Institute of Prevention and Safety (ISPELS).
  “Molecular features of malignancy and innovative therapies in pediatric solid tumors”. Italian Ministry of Health.
  “Phase II trial with Temozolomide in children and young adults with brain tumor refractory to the first- and second-line treatment”.
  “Preclinical studies on the combined therapy 125-I-MIBG and cisplatin in neuroblastoma”. Italian Ministry of University.
  “Phase II trial of Irinotecan in pediatric patients with soft tissue tumors”. Catholic University of Rome/University of Padua.
  “Phase I-II trial with Temozolomide and oral Etoposide in children with relapsed or recurrent medulloblastoma/PNET and high-grade glioma”.
  “Antitumoral activity of new atypical retinoids in medulloblastoma”.
  “Phase II trial with gemcitabine and oxaliplatin in pediatric recurrent or refractory solid tumours”.
  “Phase II trial with transdermal Buprenorphine in children with pain cancer”.
  “Phase II trial, single arm, temozolomide and topotecan in refractory and recurrent neuroblastoma and in other solid tumours”.
  “Phase II trial with intranasal midazolam by MAD (Mucosal Atomizer Device) for procedural pain”.
  “H1N1v vaccination in children with cancer”.
  “Patient Controlled Analgesia (PCA) for cancer pain in childhood”.
  “Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia (EPOC-MS-001-Doxo).
  “A phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma” (BO25041C/ITCC-019/HGG-01).
  “Liquoral neurotoxicity markers in children with acute lymphoblastic leukemia”.
  “Neural effects of topical Nerve Growth Factor (NGF) in patients with visual deficits due to optic gliomas”.
  “Predictive value of biomarkers of sepsis in children with febrile neutropenia”.
  “A phase I/II study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway and adult patients with recurrent or refractory medulloblastoma”.
  “Neurocognitive assessment in children with brain tumors”.
  “Diagnostic accuracy and Assessment of Chemotherapy Response Using FDG-PET in Pediatric Ewing sarcoma“.
  “Sviluppo di uno score per l’identificazione di bambini sottoposti a chemioterapia ad alto rischio di CINV” (Fondi Ateneo linea D.1 per progetti di ricerca).
  “An early-phase, multicenter, open-label study of the safety and pharmacokinetics of Anti-PD-L1 antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors” (Roche).
  “A phase I/II, multicenter, open-label. Dose-escalation study of the safety and pharmacokinetics of cobimetinib in pediatric and young adult patients with previously treated solid tumors”. (Roche).
  “A phase 1/2, multicenter, open-label. dosefinding, study to assess the safety, tolerability, and preliminary efficacy of weekly nab - Paclitaxel in pediatric patients with recurrent or refractory solid tumors”. (Celgene).

Research Expertise

Clinical Pharmacology; Antineoplastic Drugs; Clinical Trial; Pediatric Drugs.


News and Events


  • Special Issue on Reviews
    Acta Scientific Journals has been started Special Issue on Reviews, researchers from world wide welcoming for submission of their reviews on any topic by on/ before September 15, 2019. Special Issue is going to be released on October 01, 2019
  • Submission Timeline for Regular Issue
    Last date for submission of articles for regular Issues is September 30, 2019.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US